Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Assaf, C; Becker, JC; Beyer, M; Cozzio, A; Dippel, E; Klemke, CD; Kurschat, P; Weichenthal, M; Stadler, R.
Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology.
J Dtsch Dermatol Ges. 2013; 11(4):338-347 Doi: 10.1111/ddg.12012
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Becker Jürgen Christian
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background: Systemic treatment with pegylated liposomal doxorubicin is an established second-line treatment of advanced cutaneous T-cell lymphoma. Pegylated liposomal doxorubicin (PLD) is currently unavailable, therefore, clinical studies investigating the efficacy of non-pegylated liposomal formula (NPLD) have been analyzed. Methods: Since clinical trials comparing PLD and NPLD in CTCL do not exist, the clinical use of NPLD including safety and efficiency profile in other types of non-Hodgkin lymphoma were analyzed. Results: Clinical trials show a comparable efficacy of NPLD and PLD in non-Hodgkin lymphoma. The dosage of NPLD used in the treatment of systemic lymphoma within polychemotherapy regimens was 50 mg/m2 every three weeks. Overall response was 75-95 %, including a complete remission rate of 65-80 % and 2-and 3-year overall survival rates of 55-75 %. These data indicate that the non-pegylated formula of doxorubicin has a similar antitumor effect as the pegylated one but shows reduced cardiotoxicity. The palmoplantar erythrodysesthesia frequently observed in PLD has not been observed with the use of the NPLD. Conclusions: The clinical use of NPLD in the treatment of CTCL is reasonable. In analogy to the clinical trials of NPLD in non-Hodgkin lymphoma a dosage of 50 mg/m2 every three weeks is recommended for the treatment of CTCL.
Find related publications in this database (using NLM MeSH Indexing): Dermatology - standards; Doxorubicin - administration & dosage; Drug Carriers - chemistry; Drug Carriers -; Humans -; Lymphoma, T-Cell - drug therapy; Medical Oncology - standards; Polyethylene Glycols - chemistry; Practice Guidelines as Topic -; Skin Neoplasms - drug therapy